Literature DB >> 12406108

Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia?

Pascale Schneider, Marc Vasse, Aws Al Bayati, Bernard Lenormand, Jean-Pierre Vannier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12406108     DOI： 10.1046/j.1365-2141.2002.03835_6.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.

Authors:  Edward Allan R Sison; Rachel E Rau; Emily McIntyre; Li Li; Donald Small; Patrick Brown
Journal:  Br J Haematol       Date:  2013-01-07       Impact factor: 6.998

Review 2.  CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.

Authors:  Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Cell Mol Life Sci       Date:  2015-01-09       Impact factor: 9.261

Review 3.  Bone Marrow Aging and the Leukaemia-Induced Senescence of Mesenchymal Stem/Stromal Cells: Exploring Similarities.

Authors:  Paola Fernanda Ruiz-Aparicio; Jean-Paul Vernot
Journal:  J Pers Med       Date:  2022-04-29

Review 4.  Understanding the bone marrow microenvironment in hematologic malignancies: A focus on chemokine, integrin, and extracellular vesicle signaling.

Authors:  Edward Allan Racela Sison; Peter Kurre; Yong-Mi Kim
Journal:  Pediatr Hematol Oncol       Date:  2017-12-06       Impact factor: 1.969

5.  Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.

Authors:  Edward Allan R Sison; Emily McIntyre; Daniel Magoon; Patrick Brown
Journal:  Mol Cancer Res       Date:  2013-06-10       Impact factor: 5.852

6.  Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.

Authors:  Edward Allan R Sison; Daniel Magoon; Li Li; Colleen E Annesley; Rachel E Rau; Donald Small; Patrick Brown
Journal:  Oncotarget       Date:  2014-10-15

Review 7.  Mapping and targeting of the leukemic microenvironment.

Authors:  Matthew T Witkowski; Stavroula Kousteni; Iannis Aifantis
Journal:  J Exp Med       Date:  2020-02-03       Impact factor: 14.307

Review 8.  Toward Therapeutic Targeting of Bone Marrow Leukemic Niche Protective Signals in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Marjorie C Delahaye; Kaoutar-Insaf Salem; Jeoffrey Pelletier; Michel Aurrand-Lions; Stéphane J C Mancini
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.